What is the appropriate diagnostic work‑up and first‑line management for a patient with dense deposit disease (C3 glomerulopathy) that is immunostaining positive for laminin‑β2 (LAMB2)?

LAMB2-Positive Dense Deposit Disease: Diagnostic Work-Up and Management

Critical Diagnostic Clarification

When dense deposit disease shows positive immunostaining for laminin-β2 (LAMB2), this represents a technical artifact or non-specific staining rather than a disease-defining feature, because LAMB2 is a normal structural component of all glomerular basement membranes. The diagnosis of dense deposit disease must be confirmed by electron microscopy demonstrating highly osmiophilic, continuous intramembranous deposits, not by LAMB2 staining. 1

Mandatory Diagnostic Work-Up Before Any Treatment

1. Confirm the Diagnosis with Electron Microscopy

• Electron microscopy is the diagnostic gold standard and must show ribbon-like, highly electron-dense intramembranous deposits that are continuous and confluent along the glomerular basement membrane, appearing more osmiophilic than typical immune-complex deposits. 1
• Light microscopy typically reveals a membranoproliferative pattern with mesangial proliferation and capillary-wall thickening. 1
• Immunofluorescence must demonstrate dominant or isolated C3 staining (≥100-fold greater than any immunoglobulin) along glomerular capillary walls and mesangium. 1

2. Exclude Infection-Related Glomerulonephritis

Active or prior infection must be ruled out before labeling the case as primary dense deposit disease, because infection-related disease requires antimicrobials rather than immunosuppression. 2

• Screen for hepatitis B, hepatitis C, and HIV serologies. 2
• Obtain blood cultures and consider echocardiography if endocarditis is suspected clinically. 2
• Evaluate for chronic bacterial, fungal, parasitic, or mycobacterial infections based on clinical context. 2
• Streptococcal infection can trigger dense deposit disease in genetically predisposed individuals; check anti-streptolysin O or anti-DNase B antibodies if recent pharyngitis or skin infection occurred. 3

3. Screen for Monoclonal Gammopathy of Renal Significance (MGRS)

All adults with dense deposit disease, especially those ≥50 years, must be screened for monoclonal protein because 60–80% have a detectable monoclonal gammopathy at diagnosis. 2

• Order serum and urine protein electrophoresis with immunofixation plus serum free-light-chain analysis. 2
• If a monoclonal protein is detected, pronase-digestion immunofluorescence on paraffin-embedded tissue is mandatory to uncover masked monoclonal immunoglobulin deposits that can mimic C3-dominant disease. 4, 2
• Approximately 5–10% of cases initially classified as C3 glomerulopathy with a monoclonal gammopathy are actually membranoproliferative glomerulonephritis with masked deposits. 5, 4
• Obtain hematology consultation to evaluate for plasma-cell or lymphoproliferative disorders (MGUS, multiple myeloma, Waldenström macroglobulinemia). 2
• In roughly 30% of patients with dense deposit disease and a monoclonal gammopathy, the monoclonal protein functions as a C3 nephritic factor or anti-factor H antibody, defining an MGRS-associated disease that requires clone-directed therapy rather than standard immunosuppression. 2

4. Comprehensive Complement Assessment

Comprehensive complement testing should be performed even when serum complement levels appear normal, because dysregulation can exist without hypocomplementemia. 2

• Measure serum C3, C4, and CH50 levels; isolated low C3 with normal C4 is the typical pattern. 6, 7
• Test for C3 nephritic factor (C3NeF), which is found in approximately 80% of patients with dense deposit disease. 6, 7
• Test for anti-factor H antibodies. 2
• Order genetic testing for mutations in C3, complement factor H (CFH), factor I (CFI), factor B, CD46, and CFHR1-5 genes. 2, 6
• Many specialized complement assays are not available in routine commercial laboratories and must be sent to reference centers such as the University of Iowa or National Jewish Health. 4

First-Line Management Algorithm

If Infection Is Identified

• Primary therapy is eradication of the underlying infection with appropriate antimicrobials, plus standard supportive measures (diuretics, antihypertensives, renin-angiotensin system inhibition). 2
• Corticosteroids are reserved only for severe crescentic disease (>50% crescents with rapidly progressive renal decline). 2, 1

If MGRS Is Confirmed

• Clone-directed therapy is the cornerstone; collaborate with hematology to design regimens that may include bortezomib-based therapy, rituximab, or other agents tailored to the specific clone. 2

If Primary Dense Deposit Disease (No Infection, No MGRS)

Supportive Care (All Patients)

• Initiate an ACE inhibitor or ARB immediately and uptitrate to the maximum tolerated dose, targeting a systolic blood pressure <120 mmHg measured in the office. 1
• Restrict dietary sodium to <2 g/day (≈90 mmol) to augment the antiproteinuric effect of RAS blockade. 1
• Add potassium-wasting diuretics for volume management and to permit continued RAS blockade despite hyperkalemia. 1
• Employ potassium-binding agents when needed to maintain normal serum potassium and allow ongoing ACE-I/ARB therapy. 1
• Consider statin therapy for persistent hyperlipidemia, especially in patients with additional cardiovascular risk factors. 1

Mild Disease (Preserved Renal Function, Non-Nephrotic Proteinuria)

• Renin-angiotensin system inhibition alone for supportive care; immunosuppression should be avoided. 2

Moderate Disease (Declining Renal Function, Nephrotic-Range Proteinuria)

• First-line: a limited course of oral glucocorticoids (prednisone 1 mg/kg/day, maximum 60 mg, tapered over 3–6 months). 2
• If glucocorticoids are contraindicated, consider mycophenolate mofetil, rituximab, or cyclophosphamide. 2
• Avoid calcineurin inhibitors because long-term use can cause immune-complex-negative angiopathy and thrombotic microangiopathy. 2
• Traditional immunosuppression has limited efficacy in dense deposit disease and should generally be avoided unless crescentic disease is present. 1

Severe/Crescentic Disease (>50% Crescents, Rapidly Progressive Renal Decline)

• High-dose intravenous methylprednisolone (500–1000 mg daily for 3 days) followed by oral prednisone 1 mg/kg/day. 2
• Add cyclophosphamide (preferred over mycophenolate in rapidly progressive cases). 2, 1

Monitoring and Prognosis

• Monitor proteinuria and estimated glomerular filtration rate (eGFR) every 3 months to assess disease activity and therapeutic response. 1
• Advise patients to temporarily hold ACE-I/ARB therapy during intercurrent illnesses to reduce the risk of acute kidney injury. 1
• Dense deposit disease is associated with chronic deterioration of renal function, leading to end-stage renal disease within 10 years of diagnosis in 36–50% of patients. 6
• A ≥40% decline in estimated glomerular filtration rate over 2–3 years predicts poor renal outcome. 2
• Histological recurrence after kidney transplantation is common and may contribute to increased rates of allograft failure. 6, 7

Critical Pitfalls to Avoid

• Never diagnose dense deposit disease without electron microscopy confirmation of highly osmiophilic intramembranous deposits; C3-dominant immunofluorescence alone is insufficient. 1
• Never initiate immunosuppression before excluding infection and monoclonal gammopathy, as these conditions demand distinct therapeutic pathways. 2
• Skipping pronase-digestion immunofluorescence in patients with a monoclonal protein leads to missed masked deposit cases in 5–10% of patients. 5, 4
• Absence of hypocomplementemia does not exclude dense deposit disease; comprehensive complement profiling should be performed regardless of serum levels. 2
• LAMB2 staining is not diagnostically useful for dense deposit disease because laminin-β2 is a normal basement membrane component present in all glomeruli.